Madrigal Pharmaceuticals, Inc.
MDGL$5.10B
Mid CapNASDAQPharmaceutical Preparations🇺🇸North AmericaWEST CONSHOHOCKEN528 employees
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Mar 15, 2026
5wData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
2 upcoming, 0 past
⭐Phase 3Next
Resmetirom Phase 3 Results Expected
March 2026~Resmetirom1,000
Primary completion for Resmetirom trial (NCT04951219) in Non-Alcoholic Fatty Liver Disease
Source⭐Phase 3
Resmetirom Phase 3 Results Expected
December 2026~Resmetirom700
Primary completion for Resmetirom trial (NCT05500222) in NASH
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Resmetirom | Phase 3 | NASH | - |
MGL-3196 | Phase 3 | Heterozygous Familial Hypercholesterolemia | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
MDGL News